Taar1 is a G protein-coupled receptor (GPCR) confined to primary cilia of rodent thyroid epithelial cells. Taar1-deficient mouse thyroid follicles feature luminal accumulation of thyroglobulin suggesting that Taar1 acts as a regulator of extra-and pericellular thyroglobulin processing, which is mediated by cysteine cathepsin proteases present at the apical plasma membrane of rodent thyrocytes.
Introduction
Recently, we found the Trace amine-associated receptor 1 (Taar1), a G protein coupled receptor (GPCR), to be localized at primary cilia of rat thyrocytes, namely, FRT cells in vitro, and at antennae-like projections abundant at the apical plasma membrane domain of mouse thyrocytes in situ [1] . The apical plasma membrane of thyroid epithelial cells faces the extracellular follicle lumen, which is a location where processes occur that are essential for thyroid function. First, iodination of thyroglobulin (Tg) by thyroid peroxidase (TPO) takes place in the direct vicinity of the apical plasma membrane before Tg is stored in the follicle lumen [2, 3] . Second, the initial steps of Tg processing for thyroid hormone (TH) liberation happen at the apical plasma membrane and are mediated by cysteine cathepsins secreted into the follicle lumen upon thyroid stimulating hormone (TSH)-stimulation of thyrocytes [4e7]. The protein amounts and activities of Tg-processing cathepsins B and L in mouse thyrocytes were affected by Taar1-mediated signalling as was shown in a Taar1-deficient mouse model [8] . Interestingly, one of the Tg-processing proteases, cathepsin L, was found to be associated with primary cilia of well-polarized porcine thyrocytes upon shorteterm culture of cells isolated from thyroid tissue [9] . These findings indicated the presence of both, cathepsin L and Taar1, at cilia of differentiated thyrocytes in situ in physiological thyroid states. Because Taar1 deficiency in mice also affected TSH regulation of the thyroid gland in that TSH receptors were noncanonically localized to intracellular compartments [8] , the question arose whether TSH-dependent secretion of cysteine cathepsins, their association with the apical plasma membrane, their inhibition by cystatins and thyroglobulin-derived thyropins, or all of these, depend on Taar1 localized to primary cilia. Therefore, in this study we asked how inhibition of the thyroglobulin-processing cysteine cathepsins affects Taar1 localization at primary cilia of thyrocytes.
Functionally significant interactions of certain GPCRs, e.g. protease activated receptors (PARs) 1e4, and proteases e.g. thrombin, at the plasma membrane of epithelial cells are well documented in literature [reviewed in : 10] . Here, we extended our previous question, namely asking whether Taar1-mediated signalling affects cathepsin activities such as seen in a knock-out mouse model [8] , by deciphering whether Taar1 function at the apical plasma membrane of thyrocytes is directly linked to cysteine cathepsin activities. Therefore, we designed an in vitro study using FRT cells featuring one Taar1-positive primary cilium per cell [1, 11, 12] . Localization of Taar1 and the principal formation of primary cilia were studied by immunofluorescence, also including cells depleted of cholesterol-rich domains because those are thought to constitute cilia [13] . To enable determination of the precise sub-cellular localization, high-resolution confocal laser scanning microscopy (LSM) and z-stacking were applied. Furthermore, cathepsin activities were assessed and inhibited by activity based probes (ABP) designed by us and protease inhibitors for broad-spectrum and specific inhibition [14e17] . The results revealed that cathepsin B and L activity is required for maintenance of a fully differentiated state of thyrocytes featuring Taar1-bearing primary cilia.
Materials and methods

Cell culture
Rat thyrocytes, namely the FRT and FRTL-5 cell lines [11, 12] , were grown at 37 C with 5% CO 2 in a moisturized atmosphere. FRT and FRTL-5 cells were cultured in Coons F-12 medium (Sigma-Aldrich Chemie GmbH, Steinheim, Germany), which contained 2.68 mg/mL sodium bicarbonate and 5% fetal bovine serum (FBS) (Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany, #F7524). This medium was supplemented with a hormone mixture, consisting of 2 mg/mL insulin (Sigma-Aldrich Chemie GmbH, #I6634), 20 ng/mL Gly-His-Lys complex (Sigma-Aldrich Chemie GmbH, #G7387), 3.62 ng/mL hydrocortisone (Sigma-Aldrich Chemie GmbH, #H0135), 5 mg/mL transferrin (Invitrogen, Darmstadt, Germany, #11107e018) and 10 ng/mL somatostatin (Sigma-Aldrich Chemie GmbH, #S1763). FRTL-5 cell culture media were additionally supplemented with 1 mU/mL TSH (Sigma-Aldrich, #T-8931).
RT-PCR
An RNeasy Mini Extraction Kit (Qiagen, Hilden, Germany, #74106) was used for total RNA extraction from FRT and FRTL-5 cells, which was used as a template for cDNA synthesis. Each reaction was allowed to proceed for 60 min at 37 C and contained 10 mg of total RNA, 0.5 mM dNTPs, 1 mM of rat Taar1 anti-sense primer (instead of Oligo dT) and 4 U of reverse transcriptase. The PCR reactions on synthesized cDNA were performed at an annealing temperature of 60 C, using the following primers at 0.5 mM, each, for rat Taar1: Taar1 sense 5 0 -GTGAGAACAGTTGAGCA-3 and 5 0 -CGCAGGCAGAAGACCTGATT-3 0 anti-sense [18] , respectively, 0.2 mM dNTPs, 0.9 mM MgCl 2 , and 2 U Taq DNA polymerase (all from MBI Fermentas, St. Leon-Rot, Germany). RT-PCR products were separated through 1.5% agarose gel electrophoresis and visualized by incubation with 0.3% ethidium bromide. A FastRuler™ Low Range DNA Ladder (Thermo Fisher, Bonn, Germany, #SM1103) was used as a size marker.
Protease activity and protein biosynthesis inhibition experiments
Cathepsins B and L, as well as all cysteine peptidase activities, were inhibited in confluently grown cell cultures of FRT and FRTL-5 cells by incubation with 10 mM CA-074 (Calbiochem, Darmstadt, Germany, #205530), 10 mM cathepsin L Inhibitor III (Calbiochem, #219427), or 10 mM E64 (Enzo Life Sciences, L€ orrach, Germany, #BML-PI 107e0001), respectively, for 8 h, under otherwise standard cell culture conditions. As a vehicle control, DMSO (0.1% final concentration) was used. In additional experiments, protein de novo biosynthesis was blocked by co-treatment with 1 mg/mL cycloheximide (Sigma-Aldrich Chemie, #C7698) and protease inhibitors for 8 h. Efficiency of protein de novo biosynthesis was monitored by determination of the protein amounts of procathepsin L.
Labelling of lysosomes with LysoTracker red DND-99
In analogy to previous experiments with FRT cells [1] , confluently grown FRTL-5 cells were washed with PBS for 2 min at 37 C and incubated with 1 mM LysoTracker Red DND-99 (Molecular Probes, Leiden, Netherlands, #L-7528) in serum-free culture medium for 45 min at 37 C. Afterwards, cells were washed twice with complete culture medium for 3 min each at 37 C, followed by a chase period of 30 min in complete cell culture medium at 37 C. Cells were then washed with culture medium twice for 3 min each, before they were fixed with 4% paraformaldehyde in 200 mM HEPES, at pH 7.4, for 20 min at room temperature and stained as described below.
Activity-based probes
Protease inhibitor-treated FRT and FRTL-5 cells were washed with PBS for 2 min at 37 C, followed by incubation in serum-free medium containing 10 mM of a pan-specific ABP for cysteine peptidases, namely DCG-04 Red [14] , or a cathepsin B-selective ABP, namely NS-173 [15] , for 30 min at 37 C. Afterwards, cells were washed with complete culture medium twice for 3 min each at 37 C, followed by a chase period of 30 min in complete cell culture medium at 37 C. Cells were then washed with culture medium twice for 3 min each, and fixed with 4% paraformaldehyde in 200 mM HEPES, at pH 7.4, for 20 min at room temperature. Nuclear DNA was-counter-stained with 5 mM Draq5™ (Biostatus Limited, Shepshed, Leicestershire, UK) for 15 min at room temperature. Before mounting, cells were washed three times for 5 min each with calcium-and magnesium-free PBS (CMF-PBS) and rinsed in de-ionized water. The cells were then mounted with an embedding medium consisting of 33% glycerol and 14% Mowiol (Hoechst AG, Frankfurt, Germany) in 200 mM Tris-HCl at pH 8.5.
Cholesterol depletion by b-cyclodextrin treatment
The stability of primary cilia of FRT cells was challenged by incubation of confluently grown cultures with the cholesteroldepleting agent b-cyclodextrin (Sigma-Aldrich Chemie GmbH, #C4767). Confluent FRT cell cultures were washed with PBS at serum-free medium, under otherwise standard cell culture conditions.
Indirect immunofluorescence and cell surface staining
Protease inhibitor-, cycloheximide-, LysoTracker Red DND-99-, ABP-, and/or b-cyclodextrin-treated cells were fixed with 4% paraformaldehyde in 200 mM HEPES, at pH 7.4, for 20 min at room temperature. Next, cells were washed three times for 5 min with CMF-PBS, composed of 0.15 M NaCl, 2.7 mM KCl, 1.5 mM NaH 2 PO 4 , and 8.1 mM Na 2 HPO 4 , at pH 7.4, followed by blocking with 3% bovine serum albumin (BSA; Carl Roth GmbH, Karlsruhe, Germany) in CMF-PBS for 1 h at 37 C. Primary antibodies used in this study, namely goat anti-mouse cathepsin B (Neuromics, Hiddenhausen, Germany, #GT15047, 1:100), goat anti-mouse cathepsin L (Neuromics, #GT15049, 1:100), rabbit anti-mouse Taar1 (Antibodies Online, Aachen, Germany, #ABIN 351020, 1:50), mouse anti-rat acetylated a tubulin (Sigma-Aldrich Chemie GmbH, #T7451, 1:50), polyclonal mouse anti-human Lamp2 (DSHB, #H4B4, 1:50), and polyclonal mouse anti-human Golgin97 (Molecular Probes, #A-21270, 1:50) were diluted in 0.1% BSA in CMF-PBS. Primary antibody incubation was performed for 16 h at 4 C. Afterwards, cells were washed 6 times for 5 min with 0.1% BSA in CMF-PBS, followed by incubation with Alexa 488-or Alexa 546-conjugated secondary antibodies (Molecular Probes, Karlsruhe, Germany, #A21085, #A11070, #A11018, 1:200) for 1 h at 37 C, in the presence of 5 mM Draq5™ (Biostatus Limited) to counter-stain nuclear DNA. Specificity of secondary antibodies was confirmed by omitting primary antibodies. Specificity of the rabbit anti-mouse Taar1 antibodies was verified previously using Taar1-deficient thyroid tissue [1] .
In some experiments, glycosylated plasma membrane constituents were stained with 10 mg/mL of the biotinylated lectin Concanavalin A obtained from C. ensiformis (ConA; Sigma-Aldrich Chemie GmbH, #C2272) for 30 min at 4 C, followed by incubation with Alexa Fluor ® 546-conjugated streptavidin (Molecular Probes, Karlsruhe, Germany, #S-11225) as the secondary ConA detection label. Before mounting, cells were washed three times for 5 min each with CMF-PBS and rinsed in de-ionized water. The cells were then mounted with an embedding medium consisting of 33% glycerol and 14% Mowiol (Hoechst AG, Frankfurt, Germany) in 200 mM Tris-HCl at pH 8.5.
Image acquisition
Immunolabeled, ConA-stained, and ABP-probed cells were visualized with a confocal laser scanning microscope equipped with Argon and HeliumeNeon lasers (LSM 510 Meta; Carl Zeiss Jena GmbH, Jena, Germany). Images were obtained at a pinhole setting of one Airy unit and at a resolution of 1024 Â 1024 pixels. Micrographs were analyzed with the LSM 510 software, release 3.2 (Carl Zeiss Jena GmbH). In some experiments, immunolabeled cells were imaged using a conventional fluorescence microscope (Carl Zeiss Jena GmbH).
Image analysis and quantification of different Taar1 localization patterns
CellProfiler 2.1.1 (version 2.1.1.; available from the Broad Institute at www.cellprofiler.org [19] ) was used to determine the ratio of FRT cells displaying localization of Taar1 at primary cilia, or in compartments of the secretory pathway, to all cells. In addition, the fluorescence intensity of DCG-04 Red-positive signals, normalized to the number of cells, in protease inhibitor-treated FRT cells, was also quantified by using CellProfiler-based pipelines. The diameters of Taar1-or cathepsin L-and acetylated a tubulin-positive primary cilia, respectively, were determined morphometrically using the LSM 510 software.
TCA protein precipitation from conditioned media
Conditioned media of post-confluent cultures of FRT cells were collected after 24 h from 10-cm dishes. Conditioned media were centrifuged at 200 g for 10 min at 4 C in order to remove dead cells and cell debris. The cleared conditioned media were then incubated with ice-cold trichloroacetic acid (TCA, 10% final concentration) for 60 min at 4 C, followed by centrifugation at 13,000 g for 10 min at 4 C. The supernatants were discarded, and pellets were dried in an Eppendorf ® centrifugal vacuum concentrator (Sigma-Aldrich Chemie GmbH, #Z368172) for 15 min. The pellets were resuspended in SDS-PAGE sample buffer (10 mM Tris-HCl, pH 7.6, 0.5% SDS, 25 mM DTT, 10% glycerol and 25 mg/mL bromophenol blue). The pH was adjusted by adding 1 mL of 1.5 M Tris-HCl, pH 8.8, dropwise, until the color of the solution turned from yellow to blue, before filling up with sample buffer completely. Samples were adjusted to equal protein concentrations of the corresponding cell lysates (see below), respectively, before the TCA-precipitated proteins were separated on SDS-PAGE-gels.
Protein lysate preparation
All steps were performed on ice and centrifugations at 4 C. The FRT cells treated with protease inhibitors were washed three times for 1 min, each, with ice cold PBS before detachment with a cell scraper and collection by centrifugation at 200g for 5 min. For determination of the amounts of cellular versus secreted cathepsins, the same procedure was performed with cells after collection of the 24 h-conditioned media (see above). Afterwards, cells were resuspended in lysis buffer (20 mM Na 2 HPO 4 , 50 mM NaCl, 0.5% Triton X-100, pH 7.4), and incubated for 30 min at 4 C on an endover-end rotor. The supernatants were cleared through centrifugation for 10 min at 13,000 g and 4 C, and stored at À20 C. Protein sample concentrations were determined by the Neuhoff assay [20] .
Cathepsin B and L activity assays
Cathepsin B and L activity assays were performed as describe before [9, 21, 22] . Protein samples prepared from protease inhibitortreated FRT cells were assayed by monitoring cleavage of 10 mM In addition, 10 mM of CA-074 (Calbiochem, #205530) was added to the samples incubated with Z-Phe-Arg-AMC, to prevent the substrate's proteolysis by cathepsin B. Samples incubated with Z-Phe-Arg-AMC with addition of 10 mM CA-074 and 10 mM cathepsin L Inhibitor III were used for adjustment of background readings in cathepsin L activity assays. In parallel, in negative controls prepared for each sample, 10 mM E64 was added at the start of the reaction time. Substrate cleavage was stopped by the addition of 2 M TrisHCl (pH 9.0). The amounts of released AMC were quantified by measuring the fluorescence with a Tecan GENios Reader (Tecan Deutschland GmbH) using an excitation wavelength of 360 nm and emission reading at 465 nm.
SDS-PAGE, immunoblotting, and quantification of the proportions of cell-associated and secreted cathepsins
Proteins were separated through SDS-PAGE on 12.5% polyacrylamide gels along with a PageRuler Prestained Protein ladder (Thermo Scientific, #26616) and transferred onto nitrocellulose membranes by semi-dry blotting. Unspecific binding sites were blocked with 5% milk powder in PBS, supplemented with 0.3% Tween (PBS-T) for 16 h at 4 C. Afterwards, membranes were incubated for 2 h at room temperature with specific antibodies, namely goat anti-mouse cathepsin B (Neuromics, #GT15047, 1:1000), goat anti-mouse cathepsin L (Neuromics, #GT15049, 1:1000), and rabbit anti-human b tubulin antibodies (Abcam, #ab6046, 1:1000), diluted in PBS-T. Incubation with horseradish peroxidase-conjugated secondary antibodies (Southern Biotech, Birmingham, USA, #6160e05, #4050e05, 1:5000) was performed for 1 h at room temperature, followed by incubation with the horseradish peroxidase substrate (Pierce, Rockford, USA), and visualization through enhanced chemiluminescence onto XPosure films (Thermo Scientific).
For quantification of the proportions of secreted and cellassociated cathepsins, chemiluminescence signals were detected using the Li-Cor system (LI-COR Biosciences, Lincoln, Nebraska, USA) to avoid over-exposure. Signal intensities were then quantified from individual bands upon background subtraction using the software Image Studio Lite, version 5.2. Approx. 1.5% and 5.5% of all available protein per dish were separated by SDS-PAGE for determinations of cell-associated and secreted proteins, respectively. Therefore, dilution factor correction was used to calculate the final balances of the proportions of total protein for each, procathepsins, single and heavy chains of the two-chain forms. For documentation purposes, the immunoblots were additionally visualized onto XPosure films as explained above.
Statistical analysis
Data analysis was performed by the use of GraphPad Prism 5.01 software (GraphPad, San Diego, California, USA). The same software was used for determination of levels of significance by one-way ANOVA, followed by Tukey post hoc test.
Results
Previously, sub-cellular localization of Taar1, as well as extracellular cathepsin L, was found to be confined to the primary cilia of well-polarized FRT cells [1] and primary thyrocytes [9] , respectively. Moreover, Taar1 deficiency in mice resulted in decreased cysteine cathepsin activities [8] . Hence, potential interaction of sub-cellular localization of Taar1 with proteolytic activity of cysteine cathepsins in rat thyroid epithelial cells was analyzed in this study. As cellular models, the structurally differentiated FRT cells, which lack thyroid stimulating hormone (TSH) receptors, and the functionally differentiated, TSH receptor-bearing FRTL-5 cells were used.
Taar1 is expressed in thyroid epithelial cell lines
Total RNA was isolated from FRT and FRTL-5 cells and used as a template for cDNA synthesis, followed by PCR amplification with Taar1-specific primers. The expected products with sizes of 296 bps were detected in agarose gels, confirming Taar1 expression in the cell lines investigated herein ( Fig. 1, A-B , lanes 3e5). As Taar1 is encoded by an intron-less gene, contamination of RNA samples with genomic DNA might cause false-positive results [23] . In order to exclude contamination of samples with genomic DNA, control experiments were conducted, in which reverse transcriptase was excluded ( Fig. 1, A-B , lanes 6e8). No bands were observed in the control experiments, indicating purity of RNA samples and cDNA preparations yielding Taar1-specific amplicons.
Taar1 and cathepsin L are co-localized at the primary cilium of FRT cells
While Taar1 is following the secretory pathway to reach primary cilia of thyrocytes [1] , cathepsins are recruited out of endolysosomes for retrograde trafficking and subsequent secretion and re-association with the plasma membrane [24, 25] . Hence, here we aimed to test for possible co-localization of Taar1 with cathepsins B or L at the cilia of FRT cells. Double labelling of wellpolarized FRT cells with rabbit anti-mouse Taar1 and goat antimouse cathepsin B or L antibodies, respectively, revealed colocalization of Taar1 with cathepsin L (Fig. 2, B , arrows, yellow signals), but to a much lesser extent with cathepsin B (Fig. 2 , A, arrows, green signals) at the primary cilia. It is of interest to note that Taar1 was not co-localized with any of the two proteases in intra-cellular compartments, i.e. endo-lysosomes ( Fig. 2 , A 0 and B', arrowheads).
Cilia of FRT cells were also analyzed morphometrically, revealing an inner diameter of the Taar1-positive structures of 0.80 ± 0.29 mm ( Fig. 2, D) . The outer diameter of anti-Taar1-decorated cilia was much larger because an indirect immunostaining protocol was used, which resulted in signal enhancement and enlargement of the fluorescent structures to 1.86 ± 0.57 mm (Fig. 2 , D and C).
Conventional fluorescence microscopy allows for imaging with a focal depth larger than in confocal sections ( Fig. 2 , F cf. C). Thus, cell surface-associated structures of immunostained FRT cells were analyzed comprehensively by conventional fluorescence microscopy, demonstrating one cathepsin L-decorated cilium present in most if not all FRT cells (Fig. 2 , E, arrows) in addition to staining of numerous microvilli-like surface extensions.
The results indicated that cathepsin L, in particular, was secreted in high enough amounts to re-associate with primary cilia at the apical plasma membrane of FRT cells to become detectable by immunolabeling. In order to gain further information on the molecular forms of secreted cathepsins, proteins were TCAprecipitated from conditioned media of confluent FRT cultures and immunoblotted using cathepsin-specific antibodies. The respective cell lysates were analyzed in parallel with the proteins in conditioned media, and on the same blots, in order to determine the percentages of total protein per dish for each distinct cellassociated or secreted cathepsin form.
Cathepsins are synthesized as proforms at the rough endoplasmic reticulum (rER), followed by trafficking to the Golgi apparatus with further destination to late endosomes, where the propeptide is cleaved off to give rise to the mature forms of cathepsins. Hence, when goat anti-mouse cathepsin B antibodies were used, bands representing the heavy chain of two chain and the single chain form of cathepsin B, respectively, were detectable in the cell lysates ( Fig. 3, A, lanes 1e3 ). The TCA precipitates of two of the three corresponding conditioned media contained bands representing procathepsin B (Fig. 3 , A, lanes 5 and 6), while mature cathepsin B was only detectable in over-exposed blots (not shown). All forms of cathepsin L, namely the pro-, single chain, and two chain forms were detectable in the cell lysates ( Fig. 3, B , lanes 1e3) with the mature forms being most prominent as expected. In contrast, only small amounts of heavy chain but high amounts of procathepsin L were found to be secreted from FRT cells cultured in tight monolayers ( Fig. 3, B , lanes 4e6). The membranes were stripped off antibodies, and then incubated with rabbit anti-human b-tubulin antibodies in order to exclude the possibility of contamination of media precipitates with cell residues. Bands at approx. 55 kDa were detected in the cell lysates ( Fig. 3 , C, lanes 1e3), while a very faint band corresponding to b-tubulin was observed in only one of three conditioned media precipitates ( Fig. 3 , C, lanes 4e6), confirming that the proteins precipitated from the conditioned media of FRT cells represented secreted proteins.
The relative proportions of secreted and cell-associated pro-and mature cathepsins B and L were determined upon densitometry of the respective bands, indicating that less than 1% of cathepsin B but approx. 12% of cathepsin L were present in the conditioned media of FRT cells (Fig. 3, D) . This data supports the notion of cathepsin L secretion rates exceeding those of cathepsin B in confluent FRT cell cultures. It should be noted, however, that cilia-or microvilliassociated cathepsins are determined with the cell-associated fractions. Thus, it is difficult to conclude on the amounts of cathepsins that, upon secretion, are re-associated with cilia at the FRT cell surface, where they eventually act as proteolytically active enzymes despite the low amounts detectable by biochemical means [9] .
Inhibition of cathepsin B and L activities in monolayer cultures of FRT cells
Proteolytically active cysteine cathepsins were visualized upon incubation with the activity based probe (ABP) DCG-04 Red, a panspecific ABP for cysteine peptidases [14] . Control FRT cell cultures revealed numerous puncta over cellular profiles, resembling endolysosomes, while occasionally also dots in ring-like assemblies were discernible, i.e. reminiscent of cilia appearances (Fig. 4, A,  arrows) . The proteolytic activities of cathepsins were inhibited in FRT cells via treatment with the cathepsin B inhibitor CA-074, the cathepsin L inhibitor III, and with the broad spectrum cysteine peptidase inhibitor E64. Specificity of these inhibitors was shown by us [26, 27] and others before. The fluorescence intensity of DCG-04 Red per cell was found to be decreased in samples that were pretreated with cathepsin inhibitors (Fig. 4 , BeD, cf. A, and F), immunoblotted with anti-cathepsin B or L antibodies (A and B), and upon stripping, the identical membranes were reacted with rabbit anti-human b-tubulin antibodies (C). The amounts of secreted and cell-associated cathepsin forms, namely, the proform (pro), single chain (SC) and the heavy chain of two chain cathepsins (HC) were quantified by densitometry and are given as means plus and minus standard deviations calculated from the corresponding percentages of total protein (D), respectively. Molecular mass markers are indicated in the left margins of A-C.
suggesting that inhibitor treatment indeed resulted in inhibition of the proteolytic activities of cathepsins. DMSO treatment served as solvent control and was comparable to non-inhibited controls ( Fig. 4 , E cf. A, F).
Next, we verified accuracy of cathepsin B and L inhibition through activity assays performed with cell lysates, prepared from inhibitor-treated FRT cell cultures, and non-or DMSO-treated controls. The activity of cathepsins B and L was indeed inhibited in inhibitor-treated samples, as is shown by the lack of cleavage of their specific substrates, respectively ( Fig. 4G and H) . Cathepsin B and L activities were also inhibited in E64 treated samples ( Fig. 4G and H) as expected. DMSO treatment caused a significant decrease in cathepsin B activity in comparison to non-treated cells. However, the proteolytic activity of cathepsin B of the vehicle control was still significantly higher than that of cathepsin B inhibitor-treated cells (Fig. 4, G) . Lastly, there was no significant difference in proteolytic activity of cathepsin L between non-treated and DMSO vehicle controls (Fig. 4, H) .
Taar1 localization is confined to compartments of the secretory pathway upon inhibition of cathepsin B or L activity in FRT cells
In order to study the possible importance of cysteine cathepsin activity for the sub-cellular localization of Taar1 and its presence at primary cilia, the proteolytic activity of cathepsins was first inhibited, and the sub-cellular localization of Taar1 was then determined in FRT cells upon fixation and immunolabeling. Cathepsin B inhibitor-treated cells were thought to serve as controls as cathepsin B was not strongly co-localized with Taar1 at the primary cilia of FRT cells. It is important to note that Taar1 localization in FRT cells is heterogeneous as observed before [1] , and accordingly, Taar1 was observed at the primary cilium of some and in compartments of the secretory pathway of other FRT cells in any given monolayer (Fig. 5 , A and A', respectively). Localization of Taar1 at primary cilia was judged from their identification as acetylated a-tubulin-positive structures (Fig. 5 , green and red signals, respectively, yielding yellow signals when co-localized, arrows), while Taar1-positive secretory pathway compartments appeared reticular as previously described [1] .
In non-treated samples and vehicle controls, Taar1 was localized at the primary cilium in over 85% of the cells analyzed (Fig. 5 , A and E, arrows, G), while only 15% of the FRT cells were characterized by Taar1 localization in compartments of the secretory pathway ( Fig. 5 , A 0 and E 0 , G). Upon inhibition of cathepsin L activity and E64 treatment, this ratio was inverted such that 85% of the cells were found to contain Taar1-positive signals in the compartments of the secretory pathway ( Fig. 5 , C 0 and D 0 , arrowheads and insets, G), while Taar1 remained at cilia in only 15% of inhibitor-treated cells. Cathepsin B activity inhibition resulted in an even more pronounced effect, such that almost 95% of the cells were characterized by localization of Taar1 in compartments of the secretory pathway ( Fig. 5 , B 0 , arrowheads and inset, G). However, there were no significant differences between the various inhibitor treatments, which all resulted in Taar1 redistribution to the rER, which was in particular obvious from nuclear envelope labelling in inhibitortreated cells at the respective focal plane (Fig. 5 , B 0 eD 0 , insets). In addition, co-localization of Taar1 staining with that of the cilia marker mouse anti-rat acetylated a-tubulin was no longer revealed in most of the inhibitor-treated cells as judged from the infrequence of yellow signals at either focal plane, namely at the cells' apex and across the nuclei (Fig. 5, B -D and B 0 -D 0 , respectively). Presence or absence of cilia can also be appreciated from the respective xz-scans ( Fig. 5 , H 1 eH 5 and H 0 ).
The results indicated that cysteine peptidase activity is important to maintain localization of Taar1 at primary cilia of FRT cells. In addition, the absence of acetylated a-tubulin-positive cilia from the apexes of the majority of inhibitor-treated cells and appearance of acetylated a-tubulin-positive tubular networks around the nuclei indicated that cysteine peptidase activity is important to maintain cilia of FRT cells intact altogether.
Localization of Taar1 in the secretory pathway upon cathepsin activity inhibition is not affected by inhibition of de novo protein biosynthesis
Testing whether Taar1 is present predominantly in the rER and other compartments of the secretory pathway upon cathepsin B or L inhibition due to increased de novo biosynthesis, we blocked protein biosynthesis by cycloheximide co-treatment with cathepsin inhibitors. Thus, FRT cells were incubated with cathepsin inhibitors for 8 h in the presence of 1 mg/mL cycloheximide.
Cathepsin inhibitor-treated FRT cells without addition of cycloheximide were used as controls for this experiment (not shown).
We assumed that co-treatment of FRT cells with cathepsin inhibitors and cycloheximide could result in alterations of Taar1 localization. However, we did not observe any differences in the effect of protease-inhibitor treatment on the re-location of Taar1 from cilia to compartments of the secretory pathway between cycloheximide and inhibitor co-treated samples (Fig. 6 , A-E 0 , green signals, and G) and cultures in which no cycloheximide was used (see Fig. 5 , AeE 0 , green signals, and G). Additionally, the previously observed disappearance of primary cilia upon inhibitor treatment was also observed in cultures that were pre-treated with cycloheximide, while the controls maintained cilia (Fig. 6 , AeE', red In order to confirm inhibition of de novo protein biosynthesis in the experimental setting, proteins were isolated from FRT cells following the protease inhibitor and cycloheximide co-treatment, and immunoblotted with goat anti-mouse cathepsin L antibodies (Fig. 6, H) . The band representing the proform of cathepsin L was absent in lysates obtained from cycloheximide-treated cells, thereby confirming that de novo synthesis of proteins was blocked by incubation with 1 mg/mL of cycloheximide (Fig. 6, H) in controls, vehicle-treated cells and in the presence of protease inhibitors alike. Thus, the results indicated that it was pre-existing Taar1, which was re-located from a primary cilia-based to a predominant localization in secretory compartments of FRT cells upon treatment with cathepsin B and L inhibitors or E64.
Taar1 is retained in the compartments of the secretory pathway upon b-cyclodextrin treatment
The data above showed that Taar1 localization was dependent on cysteine cathepsin activities. In addition, in cathepsin inhibitortreated cells, primary cilia were not formed properly, or were not maintained. Thus, cathepsin inhibitor treatment caused a relocation to and retention of Taar1 in compartments of the secretory pathway, accompanied by the disappearance of primary cilia. Therefore, next we aimed to further confirm that Taar1 was retained in compartments of the secretory pathway of FRT cells due to a lack of primary cilia. In order to disrupt primary cilia, FRT cells were treated with b-cyclodextrin, which is a small amphipathic, cyclic oligosaccharide, composed of seven glucose monomers with cholesterol-chelating abilities. The b-cyclodextrins form complexes with lipids and other hydrophobic molecules, and are therefore often used to destroy cholesterol-rich sub-domains of the plasma membrane [28] . Assuming that Taar1 retention in the compartments of the secretory pathway was caused by the destruction of primary cilia upon cathepsin activity inhibition in FRT cells, disruption of primary cilia via b-cyclodextrin should cause similar effects to those obtained with cathepsin inhibitor treatment. Indeed, Taar1 was retained in the compartments of the secretory pathway upon b-cyclodextrin treatment (Fig. 7, B 0 and E, arrowheads), while it was confined to primary cilia in non-treated cells (Fig. 7, A and D, arrows) . The results reveal Taar1's presence in ß-cyclodextrin-sensitive microdomains of the apical plasma membrane of FRT cells, which are identified as cilia due to the colocalization of Taar1 and acetylated a-tubulin (see Figs. 5 and 6 above), a notion supporting our previous report of Taar1 at primary cilia in this cell line [1] .
Sub-cellular localization of Taar1 in FRTL-5 cells and absence of primary cilia
After we confirmed that Taar1 localization in FRT cells is dependent on cathepsin activity affecting the presence and maintenance of primary cilia, we aimed to determine Taar1 localization in less well-polarized, but functionally fully differentiated and thyroglobulin-synthesizing thyrocytes in vitro. To this end, FRTL-5 cells were cultured until confluence before they were fixed and co-stained with rabbit anti-mouse Taar1 antibodies and polyclonal mouse anti-human Golgin97 or polyclonal mouse anti-human lysosome-associated membrane protein 2 (Lamp2) antibodies which were used as Golgi apparatus and lysosome markers, respectively. Lysosomes of FRTL-5 cells were also stained with the fluid phase marker LysoTracker Red DND-99, and plasma membrane constituents were stained with the lectin Concanavalin A.
In FRTL-5 cells, TAAR1 was found to be localized in the compartments of the secretory pathway ( Fig. 8, A, arrowheads) , namely in the endoplasmic reticulum ( Fig. 8, B , arrowhead) and the Golgi apparatus ( Fig. 8, C, arrowhead, yellow signals) , and occasionally at the plasma membrane (Fig. 8, D and F, arrows, yellow signals). Taar1 was not observed in lysosomes of FRTL-5 cells (Fig. 8, E , arrowheads, red signals). Quantitation (data not shown) revealed Taar1 to be localized in compartments of the secretory pathway in the majority of FRTL-5 cells (Fig. 8, A, arrowheads) , while Taar1 localization at the plasma membrane was detected in only a minority of FRTL-5 cells (Fig. 8, A, arrows) . FRTL-5 cells were stained with mouse anti-rat acetylated a tubulin antibodies in order to determine the principle presence of primary cilia in this cell line. It appeared that ciliogenesis occurs in FRTL-5 cells, but it is limited to a small number of cells within the population of cultured cells (Fig. 8, G and G', arrows) .
Taar1 localization remains largely unaffected in FRTL-5 cells upon cathepsin activity inhibition
Next, we determined the effect of cathepsin activity inhibition on Taar1 localization in FRTL-5 cells, which were treated with cathepsin inhibitors as described for FRT cells and stained with rabbit anti-mouse Taar1 antibodies, while the glycoconjugates of the cell surface were counter-stained with concanavalin A.
Taar1 localization remained mainly unaltered in FRTL-5 cells upon treatment with cathepsin B or L inhibitors, and E64, in comparison to non-treated cells and vehicle control (Fig. 9AeE) . Only a few cells in the non-treated FRTL-5 cells were characterized by Taar1 prevalence at extensions of the plasma membrane, thus resembling short primary cilia ( Fig. 9, A, arrow) , while in most cells Taar1 was localized in compartments of the secretory pathway ( Fig. 9, A, arrowhead) . Upon cathepsin inhibitor treatment, Taar1 was localized in compartments of the secretory pathway in most if not all FRTL-5 cells within a given cell culture ( Fig. 9 , B-D, arrowheads). However, similar results were observed in FRTL-5 cells treated with DMSO ( Fig. 9, E, arrowheads) . Thus, Taar1 distribution in FRTL-5 cells was not affected by cathepsin inhibitor treatment. Specificity of protease inhibitor treatment of FRTL-5 cells was proved by means of labelling with the broad spectrum ABP for all cysteine peptidases DCG-04 ( Fig. 9 , A 0 -E 0 ) and the cathepsin Bspecific ABP NS-173 ( Fig. 9 , A 00 -E 00 ).
Trafficking of Taar1 to the plasma membrane of rat thyrocytes is dependent on the presence of primary cilia
Taar1 co-localization with acetylated a tubulin in FRT and FRTL-5 cells revealed that Taar1 was localized in compartments of the secretory pathway only in cells that were lacking primary cilia (Fig. 10, A-B 00 , arrowheads) . Consequently, in the presence of primary cilia, Taar1 was not retained in compartments of the secretory pathway (Fig. 10, A-B 00 , arrows) . Instead, Taar1 was localized at the primary cilia of these cells. Thus, we reasoned that presence of primary cilia might be one of the factors determining the heterogeneity in distribution and sub-cellular localization of Taar1 among cell populations of rat thyrocytes in vitro. The data indicated the necessity of primary cilia present and maintained at the apical plasma membrane in order to enable Taar1 trafficking to these antenna-like projections of rat thyrocytes. If Taar1 were indeed acting as a sensor of the colloid state [1, 7] (Fig. 11 ), the notion of Taar1's significance for TSH-regulated thyroid states [8] becomes all the more important, specifically, regarding co-regulation of cysteine cathepsin-mediated thyroglobulin processing by Taar1 at the apical cilia and the basolateral TSH receptors.
Discussion
Previously, the GPCR Taar1 was found at cilia of the apical plasma membrane domain of mouse thyrocytes in situ and rat thyrocytes in vitro, as demonstrated for FRT cells [1] . Primary cilia, typically up to a few micrometers in length and ca. 200 nm in diameter, are antennae-like projections abundant at the apical plasma membrane domain of most epithelial cells. Thyrocytes bear primary cilia which are shorter in length and broader in diameter in comparison to other epithelial cell types (this study and [1] ). The microtubular axoneme of the primary cilium is anchored in the basal body, composed of acetylated a-tubulin, and surrounded by a membrane which is distinct in its composition from the remaining plasma membrane by virtue of a so-called transition zone (reviewed in [29] ). Acetylated a- Taar1 was localized at the apical plasma membrane domain (arrows) and in the compartments of secretory pathway (arrowheads), while it was not localized in lysosomes of FRTL-5 cells (E, arrowheads). Note that primary cilia were present in distinct FRTL-5 cells (G and G 0 , arrows), only.
Nuclei were counter-stained with Draq5™ (blue signals A-F, red signals G and G 0 ). Scale bars represent 10 mm.
tubulin was used in this and our previous study [1] as a cilia marker revealing co-localization with Taar1. Primary cilia are implicated in numerous receptor-mediated signalling pathways, e.g. Hedgehog and platelet-derived growth factor receptor A signalling [30e32]. Interestingly, trafficking of membrane proteins, accumulation of cytosolic secondary messengers, and positioning of effector proteins to primary cilia are restricted by the transition zone [33] . Therefore, the protein composition of the primary cilium is distinct from the plasma membrane protein contents and, likewise, calcium and cAMP concentrations are locally distinct in the cilia-associated cytosol [31,34e38] . A lack of the primary cilium or disturbances in its length and protein composition are known from ciliopathies, diseases that affect, among other organs, the brain and kidney [39e42]. Very recently, the absence of cilia from mouse thyroid epithelial cells has been connected to the development of signs of follicular and papillary thyroid cancer [43] , indicating the importance of ciliogenesis for formation of cilia as indicators of the differentiated state of thyrocytes.
Thyroid epithelial cells are unique endocrine cells that secrete both, the thyroid hormone precursor thyroglobulin, and thyroglobulin processing proteases, the cathepsins, via their apical plasma membrane domain. Recently, Taar1-mediated signalling was shown by us to affect the protein amounts and activities of cathepsins B and L, as demonstrated in male Taar1-deficient mice [8] . Interestingly, we found cathepsin L at the primary cilia of porcine thyrocytes freshly isolated and kept in culture for few days [9] , which could suggest, in principle, a possible interaction of this protease with Taar1 at the apical pole of thyrocytes in situ. Because cathepsin L is essential for thyroglobulin processing and thyroid hormone liberation in rodents [4] , we proposed that Taar1 at cilia acts as a sensor of the state of thyroglobulin processing in the thyroid follicle lumen ( [1] ; reviewed in [7] ). Hence, here we designed a study to investigate interactions between proteolytic activity of cathepsins and sub-cellular localization of Taar1, in order to gain insights into possible interaction of cathepsin-mediated effects and Taar1-mediated signalling.
Taar1 is co-localized with cathepsin L at the primary cilia of FRT cells
In this study, we confirmed Taar1 expression in FRT cells via RT-PCR. In addition, we observed that cathepsin L is secreted from FRT cells and co-localized with Taar1 at the primary cilium. However, when we analyzed sub-cellular localization of cathepsin B in the same cell line, we found that cathepsin B is secreted in smaller amounts and is not localized at primary cilia to a similar extent. Previously, we have shown that cathepsin S was localized in vesicles distinct from vesicles containing related cathepsins in the human thyroid gland [44] . Hence, trafficking of cathepsins B and L in distinct and separate vesicles could be an underlying reason for the herein observed divergence in cathepsin B and L protein amounts secreted from FRT cells. Furthermore, the presence of binding sites specific for cathepsin L at the primary cilium of FRT cells could explain, in principle, the difference in sub-cellular In control experiments, FRTL-5 cells were treated with cathepsin inhibitors as indicated, followed by incubation with DCG-04 Red (A 0 -E 0 ) or 10 mM NS-173 Rhodamine (cathepsin Bspecific activity based probe; A 00 -E 00 ) and confocal imaging as sketched (F 0 , F 00 ), indicating specificities of protease inhibitors used.
Nuclei were counter-stained with Draq5™ (A-E, blue signals). Scale bars represent 5 mm (AeE) and 25 mm (A 0 -E 00 ). localization between cathepsins B and L. However, the nature of cathepsin binding sites at the apical plasma membrane of thyrocytes adjacent to the thyroid follicle lumen is not yet fully understood, and investigations have so far only included the aspartic cathepsin D but less attention was paid to cysteine cathepsin binding to thyrocytes [7, 17, 45] .
In other cellular systems, namely in colorectal carcinoma cells it was shown that secreted and proteolytically active cathepsin B reassociates with the plasma membrane in flask-like indentations, the caveoli [46, 47] . Additionally, cathepsin B binding sites may include the LDL-receptor related proteins [48] , the LRPs, which are present at the apical plasma membrane but not necessarily localized to cilia. In general, cathepsins can re-associate with the plasma membrane also by binding to the cation-independent mannose 6phosphate receptors, which serve in a safe-guarding system to recapture excessively secreted lysosomal enzymes, but are also not localized to cilia. Therefore, the molecular nature of cathepsin binding sites at the apical, lumen-apposed surface of thyroid epithelial cells remains elusive (see Ref. [7] for a recent review).
Sub-cellular localization of Taar1 is altered in FRT cells upon cathepsin inhibitor treatment
Several studies indicated importance of protease-mediated actions on signal transduction, transmembrane protein trafficking, and receptor processing [49, 50] . For instance, cathepsin B-mediated activity was found to prolong Toll-like receptor 2 (TLR2)/NF-К B (nuclear factor kappa-light-chain-enhancer of activated B cells) activation in fibroblasts, and the serine protease inhibitor aprotinin was proposed to affect the recycling rates and density of epithelial Na þ channels at the plasma membrane in renal cells [50, 51] .
Here, we analyzed the effects of cathepsin activity on subcellular localization of Taar1, because this GPCR at the apical surface of thyroid epithelial cells co-regulates thyroid function in mice [8] . We determined the cross-talk between cathepsins and Taar1 in a well-established and highly polarized rodent thyroid cell line, the FRT cells, upon inhibition of the proteolytic activity of cathepsin L in comparison with cathepsin B inhibitor treatment. Previously, we showed that FRT cells are characterized by heterogeneity of subcellular distribution patterns of Taar1 among individual cells of the cell population [1] . Interestingly, here we show that inhibition of the proteolytic activity of cathepsin L caused differences in the pattern of sub-cellular localization of Taar1 among FRT cells. We observed that, in contrary to non-treated cells, Taar1 was confined to the secretory pathway in the majority of cathepsin L inhibitortreated cells. Furthermore, similar effects were observed in cathepsin B inhibitor-and E64-treated cells, suggesting indirect effects of cathepsin activity inhibition on the subcellular Fig. 10 . Co-staining of Taar1 and acetylated a-tubulin in FRT and FRTL-5 cells FRT and FRTL-5 cells were stained with anti-Taar1 (green signals) and anti-acetylated a-tubulin antibodies (A-B 00 , red signals). Single confocal sections were taken at the top and median poles of FRT and FRTL-5 cells as indicated in the respective sketches (CeC 00 ). Single channels, overlays of different channels, and corresponding phase contrast micrographs are depicted as indicated. Images in A 00 and B 00 are xz-projections of z-stacks of images taken in the xy-mode, dotted lines represent the positions of the cover glasses. Note that Taar1 is localized mostly at the primary cilium of FRT cells (A-A 00 , arrows), while it is less often found at primary cilia of FRTL-5 cells (BeB 00 ). Taar1 is retained in compartments of the secretory pathway in particular in individual thyrocytes of either cell line when they lack primary cilia (A-B 00 , arrowheads).
Nuclei were counter-stained with Draq5™ (blue signals). Scale bars represent 10 mm. localization of Taar1 in FRT cells, because cathepsin L did, but cathepsin B did not co-localize to the same extent with Taar1 in FRT cells. In addition, we confirmed that the observed alterations in sub-cellular localization of Taar1 upon cathepsin B and L inhibitor treatment are not due to de novo biosynthesis of Taar1 in the endoplasmic reticulum, because the effect was not changed upon cycloheximide treatment. Therefore, we conclude that trafficking of Taar1 depends on proper cathepsin activity levels.
Moreover, we asked whether Taar1 might be retained in the secretory pathway and might not reach the primary cilium due to disturbances in its morphology and structure. In order to test the validity of this hypothesis, we determined if the primary cilium is present in FRT cells upon inhibition of the proteolytic activity of cathepsins. Cathepsin B or L inhibitor-and E64-treated FRT cell populations were composed mainly of cells that lacked a primary cilium. In order to further confirm that Taar1 is retained in the secretory pathway in the absence of a primary cilium at the apical plasma membrane domain, we disrupted the structure of the primary cilium by b-cyclodextrin treatment of FRT cells. Indeed, disruption of the primary cilia of FRT cells caused Taar1 retention in the secretory pathway. However, the molecular pathway responsible for the disappearance of primary cilia upon cathepsin inhibitor treatment remains elusive.
In order to further confirm that the presence of primary cilia is essential for Taar1 trafficking to the plasma membrane, we investigated sub-cellular localization of Taar1 in non-polarized thyrocytes lacking a primary cilium. We selected an appropriate less well-polarized rat cell lines, namely FRTL-5 cells. When confirming the expression of Taar1 in this cell line, we observed that FRTL-5 cells, like the FRT cells, from which they are derived, were characterized by little heterogeneity of Taar1 distribution among the cell population. Hence, the percentages of Taar1 prevalence in the secretory pathway and at the plasma membrane in FRTL-5 cells were highly dissimilar to FRT cells. A vast majority of FRTL-5 cells expressed Taar1 in the secretory pathway, while only a few cells in the cell population expressed Taar1 at the plasma membrane. In addition, Taar1 was localized at the plasma membrane of only those FRTL-5 cells that possessed primary cilia. It is noteworthy, that, similarly, non-treated FRT cells characterized by Taar1 presence in the secretory pathway also lacked a primary cilium.
We conclude that a primary cilium is essential for Taar1 to be trafficked to the plasma membrane of rat thyrocytes in vitro. The fact that sub-cellular localization of Taar1 was not drastically altered upon cathepsin inhibition in the less well-polarized FRTL-5 cells leads to the conclusion that the downstream action of cysteine protease inhibitors compromises the stability of the primary cilium, but does not directly affect Taar1 trafficking. Therefore, future studies will need to involve investigations on the molecular regulation of both, ciliogenesis and Taar1 transport to cilia as well as its potential diffusion for precise positioning when arrived at these cellular extensions of thyrocytes. Molecules known to affect the ultrastructure of cilia as well as the motion of proteins to and along them [52, 53] , such as intraflagellar transport 88 (Ift88) and Ift20, are expressed in mouse thyroid epithelial cells (our own unpublished observations). However, in a mouse model among others deficient in the cysteine cathepsin K that is redundantly expressed with and functionally compensated by cathepsin L in thyroid tissue, transcript levels of Ift proteins are not altered in Fig. 11 . Summarizing schematic sketch suggesting Taar1 at apical cilia as a co-regulator of cysteine cathepsin-mediated thyroglobulin processing for thyroid hormone liberation Thyroglobulin (Tg), the thyroid hormone precursor molecule, is stored in the extracellular follicle lumen in covalently cross-linked form (left). Short-term TSH receptor signalling triggers secretion of endo-lysosomal enzymes at the apical pole (red arrow) for subsequent re-association with cilia in co-localization with Taar1. Luminal cysteine cathepsinmediated thyroglobulin solubilization and processing yields release of thyropins that potentially act as cysteine peptidase inhibitors. In analogy to the results of this study, we propose that such thyropin-mediated cathepsin inhibition at the apical pole triggers disappearance of cilia and re-location of Taar1 to the endoplasmic reticulum (right). Hence, we propose that Taar1 at apical cilia (bottom left, arrows), which are present in resting follicles, acts as a sensor of thyroglobulin degradation states and co-regulates thyroid function that depends upon proteolytic action of cysteine cathepsins at extra-, peri-and intracellular locations.
